AdaptHealth (AHCO) to Release Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 7th. Analysts expect AdaptHealth to post earnings of $0.06 per share for the quarter. AdaptHealth has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

AdaptHealth (NASDAQ:AHCO) last issued its earnings results on Tuesday, February 27th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a negative net margin of 21.21% and a positive return on equity of 8.84%. The business had revenue of $858.23 million for the quarter, compared to analyst estimates of $825.94 million. On average, analysts expect AdaptHealth to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AdaptHealth Stock Performance

Shares of AHCO stock opened at $10.26 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -1.93, a PEG ratio of 0.68 and a beta of 1.06. AdaptHealth has a one year low of $6.37 and a one year high of $15.37. The company’s 50-day simple moving average is $10.32 and its 200-day simple moving average is $8.52. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.00 and a current ratio of 1.21.

Insider Buying and Selling at AdaptHealth

In other AdaptHealth news, major shareholder James E. Flynn sold 182,607 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the sale, the insider now owns 11,643,769 shares in the company, valued at $128,314,334.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder James E. Flynn sold 52,487 shares of AdaptHealth stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $10.93, for a total transaction of $573,682.91. Following the sale, the insider now directly owns 11,826,376 shares in the company, valued at $129,262,289.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn sold 182,607 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the completion of the sale, the insider now directly owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

AHCO has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 price target on shares of AdaptHealth in a report on Monday, March 4th. Truist Financial boosted their price objective on shares of AdaptHealth from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. UBS Group raised their target price on shares of AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, Jefferies Financial Group lowered AdaptHealth from a “buy” rating to a “hold” rating and lowered their target price for the company from $14.50 to $8.00 in a report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.10.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.